Trial Profile
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- 09 Sep 2022 Status changed from recruiting to completed.
- 16 May 2015 New trial record